Implantica AG

VADUZ – November 12, 2026 -- Implantica AG will publish its Q3 2026 interim report at 8:00 a.m. CET on November 19, one week after announcing the date on November 12. The company will present the results to investors at 15:00 CET the same day, which gives the market seven hours to read the report before management speaks.

The presentation will be held in English by webcast, with a separate teleconference. Webcast access is open by link. Teleconference participants must register first and will then receive a dial-in number and a conference ID.

Three executives will present the Q3 2026 results

CEO Peter Forsell, the CFO and Chief Corporate Affairs Officer Nicole Pehrsson are the announced speakers. Pehrsson is also the investor relations contact named in the release.

Implantica's shares trade on the Nasdaq First North Premier Growth Market in Stockholm under the ticker IMP A SDB. FNCA Sweden AB is the company's Certified Adviser.

Washington D.C. – September 29, 2026 -- Implantica AG launched its FDA-approved RefluxStop device in the U.S. market at the American Foregut Society (AFS) 2026 Annual Meeting, drawing an over-capacity crowd of more than 120 surgeons and gastroenterologists that forced organizers to turn away additional attendees.

FDA approval opens U.S. market for non-encircling GERD device

Following its recent Premarket Approval (PMA) from the U.S. Food and Drug Administration, RefluxStop entered a U.S. GERD treatment market estimated at 78 million patients. Unlike conventional anti-reflux surgeries that wrap around the esophagus, RefluxStop is designed to restore natural anatomy without encircling the food passageway, aiming to reduce side effects such as dysphagia and inability to belch or vomit.